Equity Research on OXiGENE Inc. and PDL BioPharma Inc. -- Biotechnology Sector Active Lately
24 Februar 2011 - 2:16PM
Marketwired
www.shinesroomonline.com has a handpicked team of market
professionals with over 100 years of combined investing experience.
Today they are providing members comprehensive research on the
biotechnology industry and are offering free analytical research on
OXiGENE Inc. (NASDAQ: OXGND) and
PDL BioPharma Inc. (NASDAQ: PDLI). Register with us
today at www.shinesroomonline.com to have free access to this
research and speak to one of our pros.
There are several headwinds that companies within the
Biotechnology sector are constantly facing. Access to capital is
historically difficult for the sector as well as intense
competition for talent and markets. Stiff competition often leads
to patent disputes for companies like PDL Bio Pharma Inc.
PDL BioPharma Inc. report is accessible for
free by registering today at
http://www.shinesroomonline.com/reports/February2411PDLBioPharmaInc.(PDLI)240211.php.
www.shinesroomonline.com is the Ultimate Trading Environment for
investors. If you are considering owning OXiGENE Inc. and PDL
BioPharma Inc. then you should sign up for a free membership and
our complimentary reports today at www.shinesroomonline.com. Over
the last 5 years our returns outpaced any of the major indexes.
Shine's performance in 2005 was +14%, 2006 + 26%, 2007 +99%, 2008 +
355% and 2009 + 46%. Sign up today to find out what you are
missing.
PDL has been involved in a few disputes lately, receiving $10
million from UCB SA for the rheumatoid arthritis drug Cimzia. It
has also disclosed a $92.5 million settlement with AstraZeneca for
an infant respiratory treatment. Visit www.shinesroomonline.com to
see how companies in this industry have grown over the past years
and how they are expected to perform in the future.
Recent funding pressures and uncertainty revolving around
research and development budgets have many companies concerned
about their operations. OXiGENE Inc. recently announced that it
will team up with the National Cancer Institute on the development
of one of its new treatments. OXiGENE Inc.
report is accessible for free by registering today at
http://www.shinesroomonline.com/reports/February2411OxigeneInc.(OXGND)240211.php.
In other news, the FDA is expected to come out with its decision
on the review process for the first copies of biologic medicines
soon. The FDA is deciding whether extensive clinical trials are
necessary for cheaper copies of drugs. There is also currently a
proposal included in the new budget that would shorten exclusivity
rights for bio-meds to seven years in order to promote competition
within the sector.
The two biotechnology stocks research
reports are available for free by signing up now on
www.shinesroomonline.com.
About Shinesroomonline.com
Shine's Room Online is the brain child of David Shine, a 15 year
Wall Street veteran with a stellar track record. For 13 years Shine
has trained thousands of traders to navigate and profit from the
markets. Using cutting edge technology, Shine provides you with a
community in which you can trade alongside Shine and his Team as
they guide you through the market's ever-changing landscape.
Contact Person: Michael Thomas Smith Marketing
Coordinator info@shinesroomonline.com
Oxigene, Inc. (MM) (NASDAQ:OXGND)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Oxigene, Inc. (MM) (NASDAQ:OXGND)
Historical Stock Chart
Von Jun 2023 bis Jun 2024